CirculationPub Date : 2026-11-07DOI: 10.1161/CIRCULATIONAHA.126.083811
Sang-Hyup Lee, Young Sup Byun, Jin Won Kim, Jae Hyoung Park, Jin-Man Cho, Woong Chol Kang, Hyuck-Jun Yoon, Won Ho Kim, Seung-Jin Lee, Jin Bae Lee, Ji-Yong Jang, Sanghoon Shin, Ik Hyun Park, Sung Uk Kwon, Sunwon Kim, Yong-Joon Lee, Seung-Jun Lee, Sung-Jin Hong, Chul-Min Ahn, Jung-Sun Kim, Young-Guk Ko, Donghoon Choi, Myeong-Ki Hong, Yangsoo Jang, Gwang-Sil Kim, Byeong-Keuk Kim
{"title":"Statin-Ezetimibe Combination Therapy versus Statin Monotherapy in Atherosclerotic Cardiovascular Disease: A Prespecified Secondary Analysis of the Randomized Ez-PAVE Trial.","authors":"Sang-Hyup Lee, Young Sup Byun, Jin Won Kim, Jae Hyoung Park, Jin-Man Cho, Woong Chol Kang, Hyuck-Jun Yoon, Won Ho Kim, Seung-Jin Lee, Jin Bae Lee, Ji-Yong Jang, Sanghoon Shin, Ik Hyun Park, Sung Uk Kwon, Sunwon Kim, Yong-Joon Lee, Seung-Jun Lee, Sung-Jin Hong, Chul-Min Ahn, Jung-Sun Kim, Young-Guk Ko, Donghoon Choi, Myeong-Ki Hong, Yangsoo Jang, Gwang-Sil Kim, Byeong-Keuk Kim","doi":"10.1161/CIRCULATIONAHA.126.083811","DOIUrl":"https://doi.org/10.1161/CIRCULATIONAHA.126.083811","url":null,"abstract":"<p><strong>Background: </strong>In a target-directed low-density lipoprotein cholesterol (LDL-C)-lowering strategy, the impact of the initial treatment regimen has not been investigated in patients with atherosclerotic cardiovascular disease. We compared the efficacy and safety of initial statin-ezetimibe combination therapy versus statin monotherapy within intensive or conventional LDL-C-targeting strategies.</p><p><strong>Methods: </strong>In this prespecified second randomization of the randomized Ez-PAVE trial (Effects of Ezetimibe Combination Therapy for Patients With Atherosclerotic Cardiovascular Disease: Randomized Comparison of LDL Cholesterol Targeting <70 versus <55 mg/dL) conducted at 17 centers in South Korea, a total of 3048 patients with atherosclerotic cardiovascular disease were enrolled between January 2021 and July 2022. Following the first randomization to either an intensive (<55 mg/dL) or conventional (<70 mg/dL) LDL-C-targeting strategy, patients underwent subsequent randomization (initial statin-ezetimibe combination therapy [n=1525] versus statin monotherapy [n=1523]) and were followed up for 3 years. Lipid-lowering therapy was adjusted according to a predefined protocol to achieve LDL-C targets. The primary end point was a 3-year composite of death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, any revascularization, or hospitalization for unstable angina.</p><p><strong>Results: </strong>The mean±SD age was 64.4±9.0 years, and 638 patients (20.9%) were female. The incidence of the primary end point did not differ between statin-ezetimibe combination therapy (128 patients [8.5%]) and statin monotherapy (119 patients [7.9%]; hazard ratio, 1.07 [95% CI, 0.83-1.37]; <i>P</i>=0.596). Patients who received statin-ezetimibe combination therapy achieved lower median LDL-C levels during follow-up than those who received statin monotherapy in both the intensive-targeting (53 mg/dL [interquartile range, 45-62 mg/dL] versus 62 mg/dL [interquartile range, 53-74 mg/dL]) and conventional-targeting (63 mg/dL [interquartile range, 55-73 mg/dL] versus 70 mg/dL [interquartile range, 62-81 mg/dL]) strategies. During follow-up, ezetimibe was added to the treatment regimen of 241 patients (34.3%) and 177 patients (24.8%) who initially received statin monotherapy in the intensive- and conventional-targeting strategies, respectively. The treatment effect of intensive-targeting versus conventional-targeting strategies was consistent regardless of therapy regimens without significant heterogeneity (<i>P</i><sub>interaction</sub>=0.583). The safety end points were similar between the groups.</p><p><strong>Conclusions: </strong>Within a target-directed LDL-C-lowering strategy, cardiovascular efficacy and safety did not differ significantly, whether initiated as statin-ezetimibe combination therapy or as statin monotherapy, but combination therapy facilitated achievement of a lower LDL-C target.</p><p><strong>Registrati","PeriodicalId":10331,"journal":{"name":"Circulation","volume":" ","pages":""},"PeriodicalIF":41.3,"publicationDate":"2026-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149370071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Leveraging AI-ECG Technology for Early Notification and Tracking of AF Development (LATENT): A Randomized Controlled Trial.","authors":"Chiao-Chin Lee, Wen-Yu Lin, Wei-Ting Liu, Chiao-Hsiang Chang, Yu-Lan Liu, Da-Wei Chang, Pang-Yen Liu, Wen-Cheng Liu, YuChih Lin, Dung-Jang Tsai, Kai-Chieh Chen, Tzu-Chiao Lin, Shu-Chen Chang, Hsin-Hui Chen, Wen-Hui Fang, Wei-Shiang Lin, Cheng-Chung Cheng, Kuan-Hsun Lin, Teng-Wei Chen, Chih-Yuan Lin, Yi-Ting Tsai, Yuan-Hao Chen, Chien-Sung Tsai, Shih-Hua Lin, C Lin, C-S Lin","doi":"10.1161/CIRCULATIONAHA.126.083540","DOIUrl":"https://doi.org/10.1161/CIRCULATIONAHA.126.083540","url":null,"abstract":"<p><strong>Background: </strong>Electrocardiographic analysis aided by artificial intelligence (AI) may identify atrial electrical vulnerability during sinus rhythm. The objective of this study was to determine whether AI-enabled ECG (AI-ECG) is effective for detecting atrial fibrillation (AF), atrial flutter (AFl), or prespecified pre-AF atrial findings in a randomized trial.</p><p><strong>Methods: </strong>In this single-center, open-label trial, 14 665 adults 40 to 85 years of age without previous AF/AFl were randomized to an AI-ECG-guided strategy or usual care. Participants randomized to AI-ECG who were then identified by AI as having a high-risk sinus-rhythm ECG in the preceding year were offered Holter monitoring for ≤7 days. Each monitored high-risk intervention participant was paired with an age- and sex-matched control selected before control ECGs underwent AI analysis. Matched controls received identical monitoring to reduce ascertainment bias. Reporting cardiologists were blinded to AI results and randomized assignment. The primary outcome was a composite of newly detected AF, AFl, or pre-AF atrial findings within 90 days. Pre-AF atrial findings comprised frequent premature atrial complexes, short runs of premature atrial complexes, or nonsustained AF/AFl.</p><p><strong>Results: </strong>Among 7337 intervention and 7328 control participants, 84 (1.1%) and 78 (1.1%), respectively, were classified as high risk. Of the 84 high-risk intervention participants, 48 (57.1%) underwent monitoring, as did 48 matched controls. The primary outcome occurred in 54 intervention participants (0.74%) versus 35 control participants (0.48%; odds ratio, 1.54 [95% CI, 1.01-2.37]; <i>P</i>=0.046). Hypothetical reclassification of 1 intervention event to a nonevent changed the primary analysis <i>P</i> value to 0.057. The intervention effect on detection of the primary composite outcome differed by baseline AI-ECG risk (<i>P</i><sub>interaction</sub><0.001): 32.1% versus 2.6% among high-risk participants and 0.4% versus 0.5% among low-risk participants. AF/AFl detection (0.3% versus 0.2%) and antiarrhythmic therapy initiation at 180 days (2.3% versus 2.4%) did not differ significantly between the intervention and control groups. Participant-reported monitoring-related adverse events, including skin reactions and discomfort, occurred in 22.9% of monitored intervention participants versus 18.8% of matched controls.</p><p><strong>Conclusions: </strong>AI-ECG-guided monitoring resulted in a modest increase in the detection of new AF, AFl, or pre-AF atrial findings. However, these findings were fragile statistically and sensitive to reclassification of 1 event. LATENT (Leveraging AI-ECG Technology for Early Notification and Tracking of AF Development) demonstrates the clinical application of AI-ECG risk stratification to guide targeted rhythm surveillance, providing a foundation for larger trials evaluating its impact on patient outcomes.</p><p><strong>Registrati","PeriodicalId":10331,"journal":{"name":"Circulation","volume":" ","pages":""},"PeriodicalIF":41.3,"publicationDate":"2026-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149370067","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
CirculationPub Date : 2026-11-03Epub Date: 2026-11-02DOI: 10.1161/CIRCULATIONAHA.126.081917
Rajat M Gupta, Peter Libby
{"title":"The Scientific Synthesis that Modernized Cardiology: A Perspective on the Formative NIH Years of Dr Eugene Braunwald (1955-1970).","authors":"Rajat M Gupta, Peter Libby","doi":"10.1161/CIRCULATIONAHA.126.081917","DOIUrl":"https://doi.org/10.1161/CIRCULATIONAHA.126.081917","url":null,"abstract":"","PeriodicalId":10331,"journal":{"name":"Circulation","volume":"154 18","pages":"1774-1776"},"PeriodicalIF":41.3,"publicationDate":"2026-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149318621","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
CirculationPub Date : 2026-11-03Epub Date: 2026-09-08DOI: 10.1161/CIRCULATIONAHA.126.080608
Noemí Ramos-López, Nerea Mora-Ayestarán, Juan Pablo Ochoa, Eduard Claver, Cristina Gómez González, Edwin Poel, Mónica García Monsalvo, Guillem Casas, Carmen Muñoz-Esparza, María Teresa Basurte-Elorz, José M Larrañaga-Moreira, Jose M García-Pinilla, María Victoria Mogollón Jiménez, Gonzalo Cabezón Villalba, Victoria Espejo Bares, María Ruiz-Cueto, Bernardo López-Abel, Ana García-Álvarez, Vicente Climent-Payá, Coloma Tirón, Eva Cabrera-Borrego, María Luisa Peña-Peña, Tomas Ripoll-Vera, Esther Zorio, Javier Sanaú, Elena Rodríguez González, Connie R Bezzina, María Gallego Delgado, José F Rodríguez-Palomares, Andrea di Marco, María Ángeles Espinosa Castro, Ahmad S Amin, Pablo García-Pavía, Jesús G Mirelis
{"title":"Arrhythmic Risk Stratification According to LGE Corridors and Genetics in Nonischemic Dilated Cardiomyopathy.","authors":"Noemí Ramos-López, Nerea Mora-Ayestarán, Juan Pablo Ochoa, Eduard Claver, Cristina Gómez González, Edwin Poel, Mónica García Monsalvo, Guillem Casas, Carmen Muñoz-Esparza, María Teresa Basurte-Elorz, José M Larrañaga-Moreira, Jose M García-Pinilla, María Victoria Mogollón Jiménez, Gonzalo Cabezón Villalba, Victoria Espejo Bares, María Ruiz-Cueto, Bernardo López-Abel, Ana García-Álvarez, Vicente Climent-Payá, Coloma Tirón, Eva Cabrera-Borrego, María Luisa Peña-Peña, Tomas Ripoll-Vera, Esther Zorio, Javier Sanaú, Elena Rodríguez González, Connie R Bezzina, María Gallego Delgado, José F Rodríguez-Palomares, Andrea di Marco, María Ángeles Espinosa Castro, Ahmad S Amin, Pablo García-Pavía, Jesús G Mirelis","doi":"10.1161/CIRCULATIONAHA.126.080608","DOIUrl":"10.1161/CIRCULATIONAHA.126.080608","url":null,"abstract":"<p><strong>Background: </strong>Fibrosis assessed through late gadolinium enhancement (LGE) in cardiac magnetic resonance imaging and genetics have emerged as risk markers of ventricular arrhythmias in nonischemic dilated cardiomyopathy. Conduction corridors detected within LGE (ie, LGE corridors) have been associated with ventricular arrhythmias in ischemic cardiomyopathy. This study sought to evaluate major ventricular arrhythmic events (MVAs) according to the presence of LGE corridors combined with high-risk genotypes (HRGs) in nonischemic dilated cardiomyopathy.</p><p><strong>Methods: </strong>We studied consecutive patients with nonischemic dilated cardiomyopathy from 22 European centers who had undergone genetic testing and cardiac magnetic resonance imaging.</p><p><strong>Results: </strong>Among 925 patients (mean age, 54.5 years [interquartile range, 43.7-63.9 years]; 64% men; mean left ventricular ejection fraction, 37.6% [26.9%-44.8%]; LGE in 24.3%), LGE corridors were present in 160 patients (17.3%), and HRG in 119 (12.9%). After a median follow-up of 5.4 years (interquartile range, 3.3-7.7), 95 patients (10.3%) experienced an MVA. In multivariable competing-risk analysis adjusted for left ventricular ejection fraction and extent of LGE, the number of LGE corridors and HRGs were independently associated with MVA (subdistribution hazard ratio, 1.25 [95% CI, 1.11-1.42]; <i>P</i><0.001; and subdistribution hazard ratio, 2.28 [95% CI, 1.32-3.96]; <i>P</i>=0.003, respectively). An optimal cutoff of ≥4 LGE corridors predicted MVA. A stepwise risk stratification algorithm to predict MVA integrating LGE, the presence of ≥4 LGE corridors, and HRG outperformed left ventricular ejection fraction ≤35%-based classification proposed in guidelines (5-year time-dependent area under the curve, 0.72 [95% CI, 0.65-0.78] versus 0.57 [95% CI, 0.51-0.64]; <i>P</i>=0.001), showing a progressive increase in arrhythmic risk across categories (Gray test <i>P</i><0.001), and allowing clinically meaningful arrhythmic risk classification.</p><p><strong>Conclusions: </strong>LGE corridors and HRGs provide additive value for arrhythmic risk stratification in patients with nonischemic dilated cardiomyopathy. These findings support MVA multiparametric prediction over the traditional left ventricular ejection fraction ≤35% threshold.</p>","PeriodicalId":10331,"journal":{"name":"Circulation","volume":" ","pages":"1791-1805"},"PeriodicalIF":41.3,"publicationDate":"2026-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148905285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
CirculationPub Date : 2026-11-03Epub Date: 2026-11-02DOI: 10.1161/CIRCULATIONAHA.126.081324
Elliott M Antman, Thomas H Lee
{"title":"Eugene Braunwald Legacy Series: Building a Framework for Academic Medicine.","authors":"Elliott M Antman, Thomas H Lee","doi":"10.1161/CIRCULATIONAHA.126.081324","DOIUrl":"https://doi.org/10.1161/CIRCULATIONAHA.126.081324","url":null,"abstract":"","PeriodicalId":10331,"journal":{"name":"Circulation","volume":"154 18","pages":"1755-1757"},"PeriodicalIF":41.3,"publicationDate":"2026-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149318612","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
CirculationPub Date : 2026-11-03DOI: 10.1161/CIRCULATIONAHA.126.080735
Pablo Garcia-Pavia, Ronald Witteles, Caroline Morbach, Diego Delgado, Hiroaki Kitaoka, Mathew S Maurer, Peter van der Meer, Ali Yilmaz, Vincent Algalarrondo, Scott D Solomon, Francesco Cappelli, Olga Azevedo, W H Wilson Tang, Olivier Lairez, Katherine L Boyle, Satish A Eraly, Yinggu Bao, Shaun Bender, John Vest, Marianna Fontana
{"title":"Long-Term Impact of Vutrisiran in Patients With TTR Amyloidosis With Cardiomyopathy: 1-Year Efficacy and Safety Outcomes From the HELIOS-B Open-Label Extension.","authors":"Pablo Garcia-Pavia, Ronald Witteles, Caroline Morbach, Diego Delgado, Hiroaki Kitaoka, Mathew S Maurer, Peter van der Meer, Ali Yilmaz, Vincent Algalarrondo, Scott D Solomon, Francesco Cappelli, Olga Azevedo, W H Wilson Tang, Olivier Lairez, Katherine L Boyle, Satish A Eraly, Yinggu Bao, Shaun Bender, John Vest, Marianna Fontana","doi":"10.1161/CIRCULATIONAHA.126.080735","DOIUrl":"https://doi.org/10.1161/CIRCULATIONAHA.126.080735","url":null,"abstract":"<p><strong>Background: </strong>In HELIOS-B (A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy), vutrisiran reduced the risk of all-cause mortality (ACM) and recurrent cardiovascular events and slowed disease progression measures versus placebo in patients with TTR (transthyretin) amyloidosis with cardiomyopathy after 33 to 36 months. We report the long-term efficacy and safety of vutrisiran from an ongoing open-label extension of HELIOS-B.</p><p><strong>Methods: </strong>Patients who completed HELIOS-B could enroll in the open-label extension, continuing with vutrisiran 25 mg every 3 months (continuous vutrisiran) or, if previously receiving placebo, initiating vutrisiran 25 mg every 3 months (placebo/vutrisiran). Prespecified end points assessed in the open-label extension are the composite of ACM and cardiovascular events, ACM, Kansas City Cardiomyopathy Questionnaire-Overall Summary score, New York Heart Association class, and NT-proBNP (N-terminal pro-B-type natriuretic peptide) and troponin I levels. Outcomes were assessed through month 48 in this analysis.</p><p><strong>Results: </strong>Of 654 participants in HELIOS-B (vutrisiran, n=326; placebo, n=328), 478 completed double-blind treatment and 466 (vutrisiran, n=243; placebo, n=223) entered the open-label extension. In the continuous vutrisiran group, the risk of first cardiovascular event or ACM was reduced by 37% (hazard ratio, 0.63 [95% CI, 0.51, 0.79]; <i>P</i>=0.0001) and ACM by 37% (hazard ratio, 0.63 [95% CI, 0.46, 0.84]; <i>P</i>=0.0023) versus the placebo/vutrisiran group. Through month 48, patients in the continuous vutrisiran group had preserved health status and quality of life per Kansas City Cardiomyopathy Questionnaire-Overall Summary score (least squares mean difference, 9.0 [95% CI, 5.3, 12.6]; <i>P</i><0.0001) and more patients had improved or stable New York Heart Association class (odds ratio, 1.6 [95% CI, 1.1, 2.2]; <i>P</i>=0.0084) versus the placebo/vutrisiran group. Benefits in the continuous vutrisiran group were maintained for NT-proBNP and troponin I levels (adjusted geometric mean fold change ratios, 0.66 [95% CI, 0.58, 0.74]; <i>P</i><0.0001; and 0.71 [95% CI, 0.64, 0.79]; <i>P</i><0.0001, respectively) versus the placebo/vutrisiran group. Similar benefits were observed in the vutrisiran monotherapy population. No new safety signals were observed.</p><p><strong>Conclusions: </strong>Long-term vutrisiran resulted in clinically meaningful benefits across mortality, cardiovascular events, cardiac biomarkers, functional status, and quality of life in patients with TTR amyloidosis with cardiomyopathy through month 48. Patients initially treated with vutrisiran had better outcomes than those first receiving placebo, highlighting the importance of early diagnosis and treatment in TTR amyloidosis with cardiomyopathy.</p><p><strong>Registration: </strong>URL: https://www.clinicaltrials.gov; Unique identifier: NCT04153149.</p","PeriodicalId":10331,"journal":{"name":"Circulation","volume":" ","pages":""},"PeriodicalIF":41.3,"publicationDate":"2026-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149318604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}